Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension;Intérêt de la substitution d'un traitement journalier de 2 instillations de timolol par 1 instillation quotidienne de bêtabloquant non conservé chez des patients présentant un glaucome chronique ou une hypertonie oculaire

Journal Francais d'Ophtalmologie

Volumn 26, Issue 7, 2003, Pages 668-674

  Bron, A ^a   Chiambaretta, F ^b   Pouliquen, P ^c   Rigal, D ^b   Rouland, J F ^d  

^a HÔPITAL DU BOCAGE   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c Laboratoires Thea   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Benzalkonium chloride; Chronic glaucoma; IOP variations; Timolol

Indexed keywords

TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INSTILLATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EYE IRRITATION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PUNCTATE KERATITIS; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AQUEOUS HUMOR; CHRONIC DISEASE; CIRCADIAN RHYTHM; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; SAFETY; TIMOLOL;

EID: 0141738517     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol, 1996;80:389-93.
2. Maurice D, Mishima S. Pharmacology of the eye. Autonomic nervous system: adrenergic antagonists, 249-277. Ed Springer-Verlag, New York, 1984.
3. Larsson LI, Rettig ES, Brubaker RF. Aqueous flow in open-angle glaucoma. Arch Ophthalmol, 1995;113:283-6.
4. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci, 1985;26:1315-9.
5. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology, 1994;101:454-60.
6. Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology, 1999;106:556-63.
7. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol, 1990;108:1543-8.
8. Broadway D, Grierson I, Hitchings R. Adverse effects of topical anti-glaucomatous medications on the conjunctiva. Br J Ophthalmol, 1993;77:590-6.
9. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol, 2002;86:418-23.
10. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology, 1997;104:334-42.
11. Schlecht LP, Brubaker RF. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology, 1988;95:1212-6.
12. Denis P, Ellena PP. Les récepteurs béta-adré nergiques vasculaires rétiniens. Ophtalmologie, 1989;3:62-4.
13. Brubaker RF. Flow of aqueous humor in humans [The Friedenwald Lecture]. Invest Ophthalmol Vis Sci, 1991;32:3145-66.
14. Koskela T, Brubaker R. The nocturnal suppression of aqueous humor flow in humans is not blocked by bright light. Invest Ophthalmol Vis Sci, 1991;32:2504-06.
15. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci, 1984;25:776-80.
16. Maus TL, McLaren JW, Shepard JW, Brubaker RF. The effects of sleep on circulating catecholamines and aqueous flow in human subjects. Exp Eye Res, 1996;62:351-8.
17. Perkins TW. Therapy of glaucoma. Textbook of Ophthalmology, Glaucoma, Vol 7, Mosby 1994;9:9.1-9.87.
18. Buguet A, Py P, Romanet JP. 24-hour (nycthemeral) and sleep-related variations of intraocular pressure in healthy white individuals. Am J Ophthalmol, 1994;117:342-7.
19. Liu JHK, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM et al. Twenty four hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci, 1999;40:2912-7.
20. Noël C, Kabo AM, Romanet JP, Montmayeur A, Buguet A. Twenty-four-hour time course of intraocular pressure in healthy and glaucomatous Africans: relation to sleep patterns. Ophthalmology, 2001;108:139-44.
21. Konstas AGP, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma, Arch Ophthalmol, 1997;115:182-5.
22. Larsson LI. Effect of intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma, 2001;10:109-14.
23. Konstas AGP, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol, 1997;115:975-9.
24. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci, 2000;4:2566-73.
25. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA, Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol, 1999;128:692-6.
26. Fechtner RD. Beta blockers. In: glaucoma therapy, principles and management. Ophthalmology monographs 13, American Academy of Ophthalmology. 1999;p25-45.
27. Zimmerman TJ, Fechtner RD. Maximal medical therapy for glaucoma. Arch Ophthalmol, 1997;115:1579-80.
28. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment Am J Ophthalmol, 2002;134:749-60.